Navigation ▼

Show simple item record

dc.contributor.advisor Stadelmann-Nessler, Christine Prof. Dr.
dc.contributor.author Behling, Felix
dc.date.accessioned 2016-09-28T09:38:59Z
dc.date.available 2016-10-04T22:50:05Z
dc.date.issued 2016-09-28
dc.identifier.uri http://hdl.handle.net/11858/00-1735-0000-002B-7C0F-5
dc.language.iso eng de
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc 610 de
dc.title Identification of Prognostically Relevant Cellular Markers of Differentiation in Glioblastoma de
dc.type doctoralThesis de
dc.contributor.referee Kramm, Christof Prof. Dr.
dc.date.examination 2016-09-27
dc.description.abstracteng Introduction: Glioblastoma multiforme is the most common primary brain tumor. Despite intense research efforts worldwide, the prognosis of patients diagnosed with this tumor remains poor. Several clinical and molecular parameters influence overall survival. However, apart from IDH-1, a prognostic marker that can be assessed immunohistochemically is still lacking. In this study the prognostic impact of several immunohistochemical markers was assessed in a cohort of 120 GBMs. Materials and Methods: In this study 120 tumor samples of patients diagnosed with glioblastoma multiforme underwent tissue microarray processing and subsequent immunohistochemical staining. All patients received adjuvant radiation and chemotherapy with an alkylating agent. The cellular expression of NogoA, OLIG2, GFAP, Ki67 and p53 and mutations of IDH-1 were assessed regarding their impact on overall survival, age and clinical status (KPS). Kaplan-Meier curve analysis (Gehan’s Wilcoxon test), the independent two-sample t-test and multivariate analysis (Cox regression) were applied. Results: A small group of patients with low GFAP expression levels showed a tendency towards younger age at the time of diagnosis, a finding yet not described in the literature. The detection of IDH-1 mutations did not show a significant prognostic impact, but a clear trend towards younger age (p=0.05063). Immunopositivity of p53 was significantly associated with longer overall survival in the Kaplan-Meier analysis (p=0.0480) and with younger age (p=0.04054) and better clinical status (p=0.01165). There was a strong trend towards longer overall survival of patients with lower expression levels of OLIG2, most pronounced at the cutoff at 30%, (p=0.0587). Interestingly, Cox regression analysis showed that expression rates of OLIG2 below 30% were a significant independent prognostic marker in glioblastoma multiforme (p=0.0168). The presence of p53 immunopositivity did not reach statistical significance in the multivariate analysis. Conclusion: In conclusion, the percentage of OLIG2 expressing tumor cells emerged as a prognostic factor for overall survival. Further studies are necessary to reveal its exact role in gliomagenesis. de
dc.contributor.coReferee Oppermann, Martin Prof. Dr.
dc.subject.eng Glioblastoma de
dc.subject.eng Immunohistochemistry de
dc.subject.eng Prognostic Markers de
dc.subject.eng OLIG2 de
dc.subject.eng P53 de
dc.subject.eng NogoA de
dc.subject.eng GFAP de
dc.subject.eng Ki67 de
dc.subject.eng Overall Survival de
dc.subject.eng IDH1 de
dc.identifier.urn urn:nbn:de:gbv:7-11858/00-1735-0000-002B-7C0F-5-2
dc.affiliation.institute Medizinische Fakultät de
dc.subject.gokfull Medizin (PPN619874732) de
dc.subject.gokfull Histopathologie {Medizin} (PPN619875704) de
dc.description.embargoed 2016-10-04
dc.identifier.ppn 869470264

Files in this item

This item appears in the following Collection(s)

Show simple item record